FCRL1 and non-Hodgkin lymphoma: The findings of this study open several promising avenues for upcoming research to advance the clinical utility of FCRL1 and BAFF in non-Hodgkin lymphoma (NHL), translating molecular insights into actionable strategies for improving diagnostic accuracy, prognostic precision, and therapeutic outcomes in DLBCL patients, especially.